Literature DB >> 8431050

Hyperbaric oxygenation for arterial air embolism during cardiopulmonary bypass.

S Kol1, R Ammar, G Weisz, Y Melamed.   

Abstract

The incidence of systemic air embolism during cardiopulmonary bypass is estimated to be 0.1%. However, the vast majority of instances are unreported and quietly ignored. The result may be disability or death. The control of air embolism obviously lies in prevention. The definite and specific treatment of this complication is hyperbaric oxygen. We report 6 patients referred to our institute because of air embolism during cardiopulmonary bypass. Of the 4 patients in whom hyperbaric oxygen therapy was delayed for 17 to 20 hours, 2 showed partial neurological improvement, as opposed to the success of hyperbaric oxygen therapy in the 2 patients in whom the delay was minimal. We conclude that as soon as the proposed open heart operation has been completed and there is an indication that air embolism has occurred, the patient should be treated with hyperbaric oxygen as quickly as possible, even before neurologic manifestations of cerebral ischemia appear.

Entities:  

Mesh:

Year:  1993        PMID: 8431050     DOI: 10.1016/0003-4975(93)91010-k

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Hyperbaric oxygen therapy in a patient with autosomal dominant polycystic kidney disease with a perinephritic abscess.

Authors:  Jorge Vega; Helmuth Goecke; Francisco Manriquez; Carlos Escobar; Max Escobar; Christian Videla; Mario Santamarina; Carlos Echeverria; Francisco Javier Guarda
Journal:  Clin Exp Nephrol       Date:  2010-10-01       Impact factor: 2.801

2.  Hyperbaric oxygen induces late neuroplasticity in post stroke patients--randomized, prospective trial.

Authors:  Shai Efrati; Gregori Fishlev; Yair Bechor; Olga Volkov; Jacob Bergan; Kostantin Kliakhandler; Izhak Kamiager; Nachum Gal; Mony Friedman; Eshel Ben-Jacob; Haim Golan
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.